Our Pipeline
Our pipeline includes Tissue-Specific Therapeutics and Tissue-Specific Biologics for soft tissue sarcoma, colorectal cancer, and inflammatory bowel disease. We believe our oncology drug candidates
will replace first-line therapies across a multitude of cancer indications. Next planned clinical trial is a Phase 2a proof-of-concept first-line-therapy study of IMX-110 as a monotherapy in soft tissue sarcoma.
Our Clinical Trials
Our lead candidate IMX-110, a potential first-line therapy for soft tissue sarcoma, is currently in clinical trials as a monotherapy, and is planned to be combined with tislelizumab (BeiGene anti-PD-1) for advanced solid tumors. IMX-111 and IMX-120 clinical trials are planned in oncology and immuno-dysregulated diseases, respectively.
Historical/Ongoing Clinical Trials
– IMX-110 Phase 1b/2a Trial: IMX-110 in Patients With Advanced Solid Tumors
Select IMX-110 Development Safety Update Report (DSUR) Summary
Scientific Posters, Publications & Reviews
– Nanotechnology-based treatment for chemotherapy-resistant breast cancer
– Metastatic Soft Tissue Sarcomas: A Review of Treatments and New Pharmacotherapies
– Constitutive Activation of NF-kB during Progression of Breast Cancer to Hormone-Independent Growth
– Development of Curcumin as an Epigenetic Agent
– Micellar Nanocarriers: Pharmaceutical Perspectives
– Cycling cancer persister cells arise from lineages with distinct programs
– Leveraging and coping with uncertainty in the response of individual cells to therapy
IMX-110 Mechanism of Action
– IMX-110 Preclinical Data Pack (Oct 2021)
– IMX-111 Preclinical Data Pack (Oct 2021)
IMX-120 Preclinical Data Pack (Oct 2021) (Undisclosed)
